Tofacitinib is used alone or with other medications to treat rheumatoid arthritis (a condition in which the body attacks its own joints causing pain, swelling, and loss of function) in adults who are unable to take or did not respond to one or more tumor necrosis factor (TNF) inhibitor medications. It is also prescribed for conditions such as psoriatic arthritis and ulcerative colitis. Tofacitinib is a Janus kinase (JAK) inhibitor that works by interfering with the inflammatory processes of the immune system.
![Butyl 4-cyano-3-imino-5-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-5-oxopentanoate](https://veeprho.com/wp-content/uploads/2022/11/Butyl-4-cyano-3-imino-5-3R-4R-4-methyl-3-methyl-7H-pyrrolo-2-3-d-pyrimidin-4-yl-amino-piperidin-1-yl-5-oxopentanoate.png "Butyl 4-cyano-3-imino-5-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-5-oxopentanoate")
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
![Ethyl 4-cyano-3-imino-5-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-5-oxopentanoate](https://veeprho.com/wp-content/uploads/2022/11/Ethyl-4-cyano-3-imino-5-3R-4R-4-methyl-3-methyl-7H-pyrrolo-2-3-d-pyrimidin-4-yl-amino-piperidin-1-yl-5-oxopentanoate.png "Ethyl 4-cyano-3-imino-5-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-5-oxopentanoate")
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
![N-methyl-N-((3S,4S)-4-methyl-1-nitrosopiperidin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-amine](https://veeprho.com/wp-content/uploads/2023/02/N-methyl-N-3S-4S-4-methyl-1-nitrosopiperidin-3-yl-6-7-dihydro-5H-pyrrolo-2-3-d-pyrimidin-4-amine.png "N-methyl-N-((3S,4S)-4-methyl-1-nitrosopiperidin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-amine")
Parent: Tofacitinib
![N-methyl-N-((3S,4S)-4-methyl-1-nitrosopiperidin-3-yl)-7-nitroso-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-amine](https://veeprho.com/wp-content/uploads/2023/02/N-methyl-N-3S-4S-4-methyl-1-nitrosopiperidin-3-yl-7-nitroso-6-7-dihydro-5H-pyrrolo-2-3-d-pyrimidin-4-amine.png "N-methyl-N-((3S,4S)-4-methyl-1-nitrosopiperidin-3-yl)-7-nitroso-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-amine")
Parent: Tofacitinib
![N-methyl-N-((3S,4S)-4-methyl-1-nitrosopiperidin-3-yl)-7-nitroso-7H-pyrrolo[2,3-d]pyrimidin-4-amine](https://veeprho.com/wp-content/uploads/2023/02/N-methyl-N-3S-4S-4-methyl-1-nitrosopiperidin-3-yl-7-nitroso-7H-pyrrolo-2-3-d-pyrimidin-4-amine.png "N-methyl-N-((3S,4S)-4-methyl-1-nitrosopiperidin-3-yl)-7-nitroso-7H-pyrrolo[2,3-d]pyrimidin-4-amine")
Parent: Tofacitinib
![N-methyl-N-(3R,4R)-(4-methyl-1-nitrosopiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine](https://veeprho.com/N-methyl-N-4-methyl-1-nitrosopiperidin-3-yl-7H-pyrrolo23-dpyrimidin-4-amine.jpeg "N-methyl-N-(3R,4R)-(4-methyl-1-nitrosopiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine")
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
![N,7-dimethyl-N-((3S,4S)-4-methyl-1-nitrosopiperidin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-amine](https://veeprho.com/wp-content/uploads/2023/02/N-7-dimethyl-N-3S-4S-4-methyl-1-nitrosopiperidin-3-yl-6-7-dihydro-5H-pyrrolo-2-3-d-pyrimidin-4-amine.png "N,7-dimethyl-N-((3S,4S)-4-methyl-1-nitrosopiperidin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-amine")
Parent: Tofacitinib
![N,7-dimethyl-N-((3S,4S)-4-methyl-1-nitrosopiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine](https://veeprho.com/wp-content/uploads/2023/02/N-7-dimethyl-N-3S-4S-4-methyl-1-nitrosopiperidin-3-yl-7H-pyrrolo-2-3-d-pyrimidin-4-amine.png "N,7-dimethyl-N-((3S,4S)-4-methyl-1-nitrosopiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine")
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
Parent: Tofacitinib
During the production and storage of Tofacitinib, related compounds and impurities may form, which must be controlled to ensure the drug’s safety and efficacy. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA), set strict guidelines on permissible impurity levels in Tofacitinib formulations.
Key aspects of Tofacitinib-related compounds and impurities include:
Advanced analytical methods, such as High-Performance Liquid Chromatography (HPLC), are used to detect and quantify Tofacitinib-related compounds and impurities, ensuring compliance with stringent safety and quality standards.
Tofacitinib is used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It helps reduce inflammation, pain, and swelling in patients who do not respond well to other treatments.
Yes, Tofacitinib is classified as an immunosuppressant because it inhibits the activity of Janus kinase enzymes involved in immune system signaling, thereby reducing inflammation and autoimmune responses.
Yes, Xeljanz (Tofacitinib) and Rinvoq (Upadacitinib) are both Janus kinase (JAK) inhibitors used to treat autoimmune conditions. While they share a similar mechanism of action, they differ in their specific indications, dosing regimens, and potential side effects.
Tofacitinib has been observed to promote hair regrowth in some patients with alopecia areata, an autoimmune condition causing hair loss. However, this is not an FDA-approved use and requires further clinical investigation.
